All > Bc Prostate Cancer > Atrial Fibrillation

Optimal Medical therapy plus ICD for Congestive Heart Failure

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Congestive Heart Failure+2 MoreOptimal Medical therapy plus CRT/ICD - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether adding pacing to both ventricles is of benefit in heart failure patients with a permanent irregular heart rhythm (atrial fibrillation).

Eligible Conditions
  • Congestive Heart Failure
  • Cardiovascular Disease
  • Atrial Fibrillation

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

2
Bromocriptine + Guideline-driven medical therapy
3
Phase 2 Empiric Heart Failure Therapy
3
Bromocriptine Treatment Arm

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: Baseline to a minimum of 18 months

Month 18
6 Minute walk distance
Perinatal death
Cardiovascular hospitalizations
Cardiovascular mortality
Composite of all-cause mortality and heart failure
Cost-effectiveness
Hospitalization for Heart Failure
Quality of Life Questionnaire
The is a reduction of Left Ventricular End Systolic Volume index (LVESVi)

Trial Safety

Safety Progress

1 of 3

Similar Trials

3
Bromocriptine + Guideline-driven medical therapy
3
Phase 2 Empiric Heart Failure Therapy
3
Bromocriptine Treatment Arm

Trial Design

2 Treatment Groups

Optimal Medical therapy plus ICD
1 of 2
Optimal Medical therapy plus CRT/ICD
1 of 2

Active Control

200 Total Participants · 2 Treatment Groups

Primary Treatment: Optimal Medical therapy plus ICD · No Placebo Group · N/A

Optimal Medical therapy plus ICD
Device
ActiveComparator Group · 1 Intervention: Optimal Medical therapy plus ICD · Intervention Types: Device
Optimal Medical therapy plus CRT/ICD
Device
ActiveComparator Group · 1 Intervention: Optimal Medical therapy plus CRT/ICD · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to a minimum of 18 months

Who is running the clinical trial?

Ottawa Heart Institute Research CorporationLead Sponsor
179 Previous Clinical Trials
87,672 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,232 Previous Clinical Trials
24,675,452 Total Patients Enrolled
Anthony SL Tang, MDPrincipal InvestigatorOttawa Heart Institute Research Corporation

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
in patients with or without structural heart disease The aim of this study is to determine the feasibility and safety of an implantable cardioverter-defibrillator (ICD) for primary or secondary prevention of sudden cardiac death (SCD) in patients with or without structural heart disease.
in patients with symptomatic HF and left ventricular dysfunction (EF ≤35%) The best possible medical treatment for heart failure lasting three or more months should be used in patients who are symptomatic and have a left ventricular dysfunction of 35% or less.
The patient has a low left ventricular ejection fraction (LVEF) of less than 35%
Patients who have had heart failure symptoms in the last 3 months and are classified as having either NYHA Class II or III symptoms will be included in the study.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top